Cargando…
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors
Because K-Ras mutation and cyclooxygenase-2 (COX-2) overexpression are hallmarks of majority of pancreatic cancer patients, an approach to inhibit the progression and growth of pancreatic cancer using the simultaneous administration of agents that inhibit the function of both targets, should be cons...
Autores principales: | DING, NING, CUI, XIAO-XING, GAO, ZHI, HUANG, HUARONG, WEI, XINGCHUAN, DU, ZHIYUN, LIN, YONG, SHIH, WEICHUNG JOE, RABSON, ARNOLD B., CONNEY, ALLAN H., HU, CHUNHONG, ZHENG, XI |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063540/ https://www.ncbi.nlm.nih.gov/pubmed/24647860 http://dx.doi.org/10.3892/ijo.2014.2350 |
Ejemplares similares
-
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib
por: WANG, HUAQIAN, et al.
Publicado: (2014) -
Tipifarnib in the treatment of acute myeloid leukemia
por: Thomas, Xavier, et al.
Publicado: (2007) -
Atorvastatin-induced pancreatitis
por: Prajapati, Samir, et al.
Publicado: (2010) -
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008) -
Tipifarnib prevents development of hypoxia-induced pulmonary hypertension
por: Duluc, Lucie, et al.
Publicado: (2017)